Over the years, China’s biopharmaceutical segment has grown to represent a significant share of the overall pharmaceutical industry. Innovation trends, enhanced regulations, and lucrative funding from both public and private sources, are some of the primary factors responsible for the establishment and success of a number of biopharmaceutical contract manufacturers in China. As per our analysis, for the period 2020-2030, the market is expected to witness a CAGR of 12.7% and is likely to worth around USD 2.6 billion by 2030.


The revenues in 2020, are expected to be dominated by the manufacturers offering API contract manufacturing service (51%). While FDF contract manufacturing service (49%) is expected to contribute a share of 49%, in 2020.


Further, the maximum opportunity, in terms of revenues generated in the biopharmaceutical contract manufacturing domain in China is estimated to be associated with mammalian expression systems. Based on our analysis, 70% of revenues are anticipated to come Chinese biopharmaceutical contract manufacturers that utilizes mammalian expression systems for the production of biopharmaceuticals. This is followed by the Chinese biopharmaceutical contract manufacturers that utilizes microbial expression systems (25%). This trend is likely to thrive over the coming decade as well.



In terms of scale of operation, currently the contract manufacturing market for commercial scale operations (81%) is likely to dominate in China. This is followed by the market revenues generated from preclinical / clinical scale operations, which is likely to contribute more than 15% of the total share in this domain.


Further, major proportion (40%) of the current market is expected to be with the large and very large companies. This is followed by the revenues generated by the small companies, which are likely to contribute 35% to this domain.


In terms of biologic, as per our estimates, in 2020, the major contribution to the market is expected to be made by vaccines and other biologics, contributing 42% each, followed by antibodies (16%). In 2030 as well, vaccines (43%) is likely to contribute towards majority share of the market, followed by other biologics (41%) and then antibodies (16%).